Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Aldeyra Therapeutics, Inc. | aldx-ex312_12.htm |
| EX-31.1 - EX-31.1 - Aldeyra Therapeutics, Inc. | aldx-ex311_9.htm |
| 10-K - 10-K - Aldeyra Therapeutics, Inc. | aldx-10k_20201231.htm |
| EX-32.1 - EX-32.1 - Aldeyra Therapeutics, Inc. | aldx-ex321_8.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Aldeyra Therapeutics, Inc.
Lexington, Massachusetts
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-226266) and Form S-8 (Nos. 333-196674, 333-203076, 333-210492, 333-213045, 333-217043, 333-224019, 333-230161, and 333-237129) of Aldeyra Therapeutics, Inc. of our report dated March 11, 2021, relating to the consolidated financial statements, which appear in this Annual Report on Form 10-K.
/s/ BDO USA, LLP
Boston, Massachusetts
March 11, 2021